|
Market Closed -
Hong Kong S.E.
04:08:27 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 0.4500 HKD | -5.26% |
|
+20.00% | -10.00% |
| 08-28 | Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 06-24 | Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection) | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 237M | - | - | - | - | - |
| 74.46B | |||||
| 60.14B | |||||
| 48.15B | |||||
| 44.25B | |||||
| 43.99B | - | - | - | - | - |
- Stock Market
- Stocks
- 2181 Stock
- Charts Mabpharm Limited
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
